NCT05975554View on ClinicalTrials.gov

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

September 1, 2025

Conditions

TIACarotid Artery PlaqueCarotid Atherosclerosis

Interventions

DRUG

Interleukin-2 [IL-2]

5 sequential days of treatment (1.5MIU/day subcutaneously)

PROCEDURE

Standard care - Carotid Endarterectomy

Standard care for patients with carotid stenosis undergoing carotid endarterectomy

Trial Locations (1)

CB2 0QQ

Addenbrookes Hospital, Cambridge

All Listed Sponsors

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT05975554 - The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. | Biotech Hunter | Biotech Hunter